Mon, Jul 14, 2014, 6:44 AM EDT - U.S. Markets open in 2 hrs 46 mins


% | $
Quotes you view appear here for quick access.

Pharmacyclics Inc. Message Board

auntkanga 2 posts  |  Last Activity: Jun 30, 2014 10:30 AM Member since: Dec 30, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Pharmacyclics (NASDAQ:PCYC)‘s stock had its “outperform” rating reaffirmed by stock analysts at Credit Suisse in a report issued on Monday. They currently have a $121.00 target price on the stock. Credit Suisse’s target price indicates a potential upside of 36.75% from the company’s current price.

    The analysts wrote, “We are raising our Q2 US Imbruvica sales forecast to $94M from $80M, based on recent IMS prescription and sales trends (now above the $80M guidance for Q2:14). Our full year sales estimate increases to $362M from $330M, and our 2014 EPS increases to $0.65 from $0.52. We expect PCYC will raise its overly conservative Imbruvica guidance.”

  • auntkanga auntkanga Jun 21, 2014 2:02 AM Flag

    TLSR: Pharmacyclics' supplemental new drug application [sNDA] for Imbruvica [ibrutinib] was recently granted priority review by the FDA for treatment of chronic lymphocytic leukemia [CLL]. Is that the catalyst you were looking for, or is there more news to come?

    JM: At ASCO, partners Johnson & Johnson and Pharmacyclics sponsored several symposia on CLL, and the Phase III RESONATE trial data was presented - and simultaneously published in the New England Journal of Medicine with major fanfare. The common term used among researchers at the conference and analysts after the presentations was "SOC," meaning Imbruvica is on its way to becoming the new "standard of care" for the treatment of CLL, the most common form of B-cell blood cancer.

    In our view, ASCO data, including duration of response results now exceeding an astonishing 3 years, further solidifies the drug in the eyes of hematologists/oncologists. As Dr. Susan O'Brien from MD Anderson Cancer Center put it, "Imbruvica is the easiest drug I've ever prescribed." Prescription data recently spiked, and that was before the conference.

    A post-ASCO pop is likely over the next few weeks. In addition, the FDA just accepted the company's sNDA application for a full CLL/small lymphocytic lymphoma [SLL] label, giving Imbruvica a priority review and setting a PDUFA date for Oct. 7. While some believe AbbVie Inc.'s (ABBV) ABT-199 has a chance to dethrone Imbruvica someday, most ASCO watchers note that its tumor lysis syndrome profile has hardly been fixed, and that its use in the community will be very difficult, especially compared with Imbruvica.

    The train doesn't stop there, as Pharmacyclics' autoimmune compound, which has even greater commercial opportunity and financial leverage, will emerge later this year. In our view, investors will begin to appreciate the next leg up in the Pharmacyclics value proposition being created in autoimmune.

95.69-1.47(-1.51%)Jul 11 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.